atovaquone (Mepron)
Jump to navigation
Jump to search
Introduction
Tradename: Mepron.
Indications
- treatment of mild to moderately severe Pneumocystis pneumonia (PCP) in patients intolerant of trimethoprim/sulfamethoxazole
- prophylaxis for Pneumocystis pneumonia
- used in combination with proguanil in Malarone for prophylaxis & treatment of chloroquine-resistant malaria
- treatment of babesiosis
- treatment of toxoplasmosis Warnings: use with caution in elderly patients
Dosage
750 mg PO BID[1], TID[2] for 21 days
Suspension: 750 mg/5 mL (210 mL).
Pharmacokinetics
- absorption increased by food
elimination via liver
Adverse effects
- common (>10%)
- less common (1-10%)
- asthenia, dizziness, pruritus, hypoglycemia, hyponatremia, abdominal pain, constipation, anorexia, dyspepsia, anemia, neutropenia, leukopenia, elevated BUN/creatinine, cough, elevated amylase & liver enzymes, oral Monilia
Drug interactions
- rifampin decreases atovaquone levels
- zidovudine increases atovaquone levels
Laboratory
More general terms
Component of
References
- ↑ 1.0 1.1 The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ 2.0 2.1 Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
- ↑ Prescriber's Letter 7(8):48 2000
- ↑ Department of Veterans Affairs, VA National Formulary
- ↑ Deprecated Reference